Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer
NCT00005825CI-TRIAL-00013034unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| mitomycin C | Drug | Mitomycin | ALIAS |
| tretinoin | Drug | Tretinoin | ALIAS |
| vinorelbine tartrate | Drug | Vinorelbine | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed stage IIIB or IV non-small cell lung cancer * Measurable disease * No brain metastases PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Zubrod 0-2 Life expectancy: * Not specified Hematopoietic: * Absolute granulocyte count greater than 2,000/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic: * Bilirubin less than 2 times upper limit of normal (ULN) * AST and ALT less than 2.5 times ULN (unless attributed to liver metastases) Renal: * Creatinine no greater than 1.5 mg/dL AND/OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No myocardial infarction within past 6 months * No congestive heart failure * No uncontrolled arrhythmia Other: * No other concurrent or prior malignancy within past 5 years except localized basal cell or squamous cell skin cancer * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 4 weeks since prior radiotherapy with clearly progressive disease * Concurrent palliative radiotherapy allowed if no evidence of disease progression Surgery: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.